Collegium Pharmaceutical, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing condensed consolidated balance sheet data and other financial information as of that date.

Key Highlights

  • Total assets: Collegium reported total assets of $2,135,790 thousand as of June 30, 2026, up from $1,656,834 thousand at December 31, 2025.
  • Cash and cash equivalents: Cash and cash equivalents were $129,467 thousand at June 30, 2026, compared to $231,252 thousand at December 31, 2025.
  • Intangible assets: Net intangible assets increased to $1,186,084 thousand from $669,510 thousand at year-end 2025.
  • Goodwill: Goodwill rose to $190,177 thousand from $145,925 thousand at December 31, 2025.
  • Accrued rebates, returns and discounts: This liability grew to $406,854 thousand from $318,266 thousand at December 31, 2025.
  • Shares outstanding: As of July 31, 2026, there were 32,555,613 shares of Common Stock, $0.001 par value per share, outstanding.

Collegium Pharmaceutical Balance Sheet Shifts in the First Half of 2026

According to the filing, Collegium Pharmaceutical, Inc. (NASDAQ: COLL) reported a substantial expansion of its asset base between December 31, 2025 and June 30, 2026. Total assets grew to $2,135,790 thousand from $1,656,834 thousand, driven in part by a significant increase in net intangible assets, which reached $1,186,084 thousand compared to $669,510 thousand at year-end 2025. The company also disclosed an increase in goodwill, from $145,925 thousand to $190,177 thousand, which the filing associates in part with business combination activity, including a reference to Azstarys acquisition integration among forward-looking considerations.

The filing indicates that inventory rose sharply, reaching $113,269 thousand at June 30, 2026, up from $40,912 thousand at December 31, 2025. Accounts receivable, net, also increased to $285,102 thousand from $211,328 thousand. Offsetting these increases, cash and cash equivalents declined to $129,467 thousand from $231,252 thousand, and the company's marketable securities balance fell to zero from $155,427 thousand at December 31, 2025, according to the balance sheet data presented in the filing.

On the liabilities side, the filing reported that accrued rebates, returns and discounts increased to $406,854 thousand from $318,266 thousand at year-end. The current portion of term notes payable rose to $55,000 thousand from $29,000 thousand. A business combination consideration payable of $29,719 thousand was also listed as of June 30, 2026, compared to $17,5 thousand at December 31, 2025, though the latter figure appears truncated in the source text. The company is classified as a large accelerated filer.

What Was Disclosed

Collegium Pharmaceutical filed its Form 10-Q for the quarter ended June 30, 2026, disclosing unaudited condensed consolidated balance sheet data reflecting growth in total assets, intangible assets, inventory, and liabilities, alongside a decline in cash and marketable securities from year-end 2025 levels.